Combined with our previous studies, berberine can deplete tumor polyamines and inhibit ODC expression, ultimately inhibiting tumor growth, reducing intestinal permeability in CRC patients, and downregulating MYC and HIF1α (36). This evidence concerns the gene MYC and colorectal carcinoma.